Caxton Associates (New York)’s Boston Scientific BSX Stock Holding History

Caxton Associates (New York)’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$62.6M	Buy	701,105 +1,105	+0.2%	+$97.3K	1.97%	7
2024 Q3	$58.7M	Buy	+700,000	New	+$55.2M	2.2%	6
2023 Q1	–	Sell	-50,000	Closed	-$2.31M	–	505
2022 Q4	$2.31M	Hold	50,000	–	–	0.15%	37
2022 Q3	$1.94M	Buy	+50,000	New	+$2.01M	0.26%	34
2020 Q4	–	Sell	-75,000	Closed	-$2.87M	–	159
2020 Q3	$2.87M	Buy	+75,000	New	+$2.89M	0.3%	31
2019 Q2	–	Sell	-21,840	Closed	-$838K	–	406
2019 Q1	$838K	Buy	+21,840	New	+$834K	0.12%	89
2018 Q4	–	Sell	-6,499	Closed	-$250K	–	296
2018 Q3	$250K	Buy	+6,499	New	+$227K	0.02%	348
2018 Q1	–	Sell	-44,975	Closed	-$1.11M	–	332
2017 Q4	$1.11M	Buy	+44,975	New	+$1.24M	0.05%	193
2017 Q2	–	Sell	-20,100	Closed	-$500K	–	471
2017 Q1	$500K	Buy	+20,100	New	+$489K	﹤0.01%	245
2015 Q2	–	Sell	-225,000	Closed	-$3.99M	–	152
2015 Q1	$3.99M	Buy	+225,000	New	+$3.56M	0.17%	99

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caxton Associates (New York)'s BSX Position: Q4 2024 in Review

Caxton Associates (New York) increased its Boston Scientific (BSX) stake by 0.16% in Q4 2024, buying an estimated $97.3K and bringing the position to 701,105 shares worth $62.6M. The position accounts for 1.97% of the portfolio, ranked #7.

Caxton Associates (New York) first reported a position in BSX in Q1 2015 and has held it in 10 quarters since. 1,512 funds tracked by Wall St. Rank hold BSX as of Q4 2024.

Caxton Associates (New York) held 701,105 shares of Boston Scientific worth $62.6M as of Q4 2024.
Caxton Associates (New York) bought 1,105 Boston Scientific shares in Q4 2024, an estimated $97.3K.
Boston Scientific made up 1.97% of Caxton Associates (New York)'s portfolio in Q4 2024, its #7 holding.
Caxton Associates (New York) first reported a position in Boston Scientific in Q1 2015 and has held it in 10 quarters since.
1,512 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.